Vaccines

The FDA’s decision to expand eligibility for the Pfizer vaccine to young kids could mean less illness, safer school and more freedom

As U.S. Food and Drug Administration advisers recommend authorizing shots for children aged five to 11, researchers predict what this might mean for populations

A new book reveals how quiet scientists, big drug companies and the Trump administration raced to meet the COVID threat—and why kids are just now being considered for shots

Companies are updating vaccines and testing them on people to prepare for whatever comes next in the pandemic

Today we bring you a new episode in our podcast series COVID, Quickly. Every two weeks, Scientific American’s senior health editors Tanya Lewis and Josh Fischman catch you up on the essential developments in the pandemic: from vaccines to new variants and everything in between.

You can listen to all past episodes here.

Wealthy countries have bought up most of the available vaccine doses for booster shots but still have far more than they need

Now that the FDA has authorized the shots for a broad range of Americans, many people want to know if they need a booster dose. Here’s what we have learned so far

The WHO-approved RTS,S vaccine has a modest efficacy and requires a complex regimen of doses, so ample funding and clear communication are crucial to success

Studies show the vaccines against the disease not only can be safely given to people who are expecting but can also save lives

The number of pregnant people suffering from severe COVID is preventable tragedy

The actual number who resign rather than get the vaccine is much smaller than the survey data suggest

Pfizer expects to have safety and efficacy data on five- to 11-year-olds by the end of the month, but federal authorities must still review it